Longeveron Unveils Promising Phase 2a Results for Regenerative Medicine and Cell Therapy in Mild Alzheimer’s Disease at AAIC 2024
Longeveron Inc., a leader in regenerative medicine and cell therapy, recently presented groundbreaking findings from their Phase 2a CLEAR MIND trial of Lomecel-B™ at the Alzheimer’s Association International Conference (AAIC) 2024. The trial focused on the efficacy and safety of Lomecel-B™, a medicinal signaling cell therapy, in treating mild Alzheimer’s Disease. Key Highlights: Implications for […]
Breakthrough in Alzheimer’s Treatment: Lomecel-B™ Receives RMAT Designation from FDA
Longeveron Inc., a clinical stage regenerative medicine biotechnology company, has achieved a significant milestone in the fight against Alzheimer’s Disease. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease. This designation underscores the potential of Lomecel-B™ to provide a new […]